ACA Pharma

Fast-Track Market Entry for U.S. & EU Biopharma in China via Macau At ACA Pharma, we specialize in accelerating market access for innovative orphan drugs, pediatric medicines, and new therapies in China through Macau’s 30-90 day fast-track registration pathway—with 100% success rate. 📌 Immediate Market Access & Long-Term Growth Once registered in Macau, medications gain access to Greater China, including: ✔ Greater Bay Area (GBA) hospitals (Guangdong, Hong Kong, Macau) ✔ Hainan & Tianjin hospitals (via real-world clinical use) ✔ Top Beijing & Shanghai hospitals for orphan & pediatric drugs 📌 Zero Additional Investment for Originators ✔ No national trials required ✔ No upfront investment—ACA Pharma covers all costs ✔ Immediate revenue post-approval through our CSO model ✔ IP fully protected—originators retain ownership 📌 Proven Results: 54+ Successful Registrations We have registered over 54 U.S. & EU drugs in Macau, securing fast-track market access for leading biopharma companies. Our latest success: Eagle Pharmaceuticals’ Ryanodex approval, with a pathway toward Greater Bay Area hospitals and China’s national registration without clinical trials. 📌 From Macau to National Registration in 6-12 Months ✔ Urgent-use & orphan drugs: National approval in 6-12 months (no full trials) ✔ Pediatric orphan drugs: National approval in 3-6 months (minimal real-world cases) ✔ Large-scale insurance coverage potential via China’s National Medical Insurance (NMI) 💡 Interested in entering China’s market without lengthy national trials? 📩 Contact us at: www.acapharma.net #FastTrackRegistration #OrphanDrugs #ChinaMarket #Biopharma #Healthcare #ACAPharma #PharmaExpansion #RegulatoryStrategy